Figure 4. CD45RO+CD8+ T cells inhibit ccRCC progression, while CD45RO predicts poor prognosis. CD45RO level from database and clinical specimen were analyzed to explore the potential clinical diagnose and treat value. (A) UCHL1 transcript level in 24 cancers tissues compare to normal tissues. (B) Statistics of IHC positive rate of CD45RO in ccRCC tissues and normal renal tissues. (C, D, E, F) UCHL1 transcript levels of colonic adenocarcinoma (COAD) (C), uterine corpus endometrial carcinoma (UCEC) (D), kidney renal clear cell carcinoma (KIRP) (E) and kidney renal clear cell carcinoma (KIRC) (F). (G) UCHL1 transcript levels of normal renal tissues and different degree ccRCC tissues. (H, I, J) We injected 108 CD45RO+CD8+ T cells or CD45RO+CD8+ T cells per week after ccRCC model successfully established. Survival time, tumor growth rate and tumor weight were recorded.